These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 16448441)

  • 1. Discovery of a pituitary adenoma following treatment with a gonadotropin-releasing hormone agonist in a patient with prostate cancer.
    Massoud W; Paparel P; Lopez JG; Perrin P; Daumont M; Ruffion A
    Int J Urol; 2006 Jan; 13(1):87-8. PubMed ID: 16448441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of a pituitary adenoma following a gonadotropin-releasing hormone agonist in a patient with prostate cancer.
    Massoud W; Paparel P; Lopez JG; Perrin P; Daumont M; Ruffion A
    Int J Urol; 2006 Mar; 13(3):303-4. PubMed ID: 16643633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gonadotropin-releasing hormone: an update review of the antagonists versus agonists.
    Van Poppel H; Klotz L
    Int J Urol; 2012 Jul; 19(7):594-601. PubMed ID: 22416801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance to luteinizing hormone releasing hormone agonist therapy for metastatic prostate cancer.
    Curry EA; Sweeney CJ
    J Urol; 2002 Jul; 168(1):193. PubMed ID: 12050525
    [No Abstract]   [Full Text] [Related]  

  • 5. Pituitary apoplexy following gonadotropin-releasing hormone agonist administration with gonadotropin-secreting pituitary adenoma.
    Sasagawa Y; Tachibana O; Nakagawa A; Koya D; Iizuka H
    J Clin Neurosci; 2015 Mar; 22(3):601-3. PubMed ID: 25455737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implications of androgen-deprivation therapy in patients with prostate cancer: A case study.
    Doyle-Lindrud S
    Clin J Oncol Nurs; 2006 Oct; 10(5):565-6. PubMed ID: 17063610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gonadotropin releasing hormone analogue antiandrogen failure secondary to a pituitary adenoma.
    Ogan K; Berger M; Ball R
    J Urol; 1998 Aug; 160(2):497-8. PubMed ID: 9679910
    [No Abstract]   [Full Text] [Related]  

  • 8. Intracranial metastatic prostate carcinoma presenting as intermittent double vision.
    Saito Y; Kondo Y; Shimizu H; Kunimoto K; Nishimura T
    Urology; 2004 Sep; 64(3):589-90. PubMed ID: 15351603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Failure of gonadotropin-releasing hormone agonists with and without sterile abscess formation at depot sites: insight into mechanisms?
    Daskivich TJ; Oh WK
    Urology; 2006 May; 67(5):1084.e15-7. PubMed ID: 16698377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
    Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
    BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Granulomas induced by subcutaneous injection of leuprorelin acetate.
    Sakamoto R; Higashi Y; Mera K; Kanekura T; Kanzaki T
    J Dermatol; 2006 Jan; 33(1):43-5. PubMed ID: 16469084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer.
    Boccon-Gibod L; Iversen P; Persson BE
    Expert Rev Anticancer Ther; 2009 Dec; 9(12):1737-43. PubMed ID: 19954284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pituitary apoplexy after leuprolide.
    Davis A; Goel S; Picolos M; Wang M; Lavis V
    Pituitary; 2006; 9(3):263-5. PubMed ID: 16832587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Localized amyloidosis of the seminal vesicle. Possible association with hormonally treated prostatic adenocarcinoma.
    Unger PD; Wang Q; Gordon RE; Stock R; Stone N
    Arch Pathol Lab Med; 1997 Dec; 121(12):1265-8. PubMed ID: 9431316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prostatic cancer with cystic formation: a case report].
    Kubo M; Taguchi K; Fujisue H; Ihara H; Ikoma F
    Hinyokika Kiyo; 1998 Dec; 44(12):883-6. PubMed ID: 10028435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pituitary apoplexy induced by Gonadotropin-releasing hormone agonists for treating prostate cancer-report of first Asian case.
    Huang TY; Lin JP; Lieu AS; Chen YT; Chen HS; Jang MY; Shen JT; Wu WJ; Huang SP; Juan YS
    World J Surg Oncol; 2013 Oct; 11():254. PubMed ID: 24088191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unexpected enlargement of clinically silent pituitary gonadotroph adenoma induced by goserelin acetate given as treatment for prostate cancer.
    Ito Y
    Int J Urol; 2011 Jan; 18(1):83-4. PubMed ID: 21077963
    [No Abstract]   [Full Text] [Related]  

  • 18. [Two cases of non-functional gonadotroph adenoma pituitary apoplexy following GnRH-agonist treatment revealing gonadotroph adenoma and pseudopituitary apoplexy after GnRH administration].
    Hernandez Morin N; Huet D; Hautecouverture M
    Ann Endocrinol (Paris); 2003 Jun; 64(3):227-31. PubMed ID: 12910066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pituitary apoplexy after leuprolide administration for carcinoma of the prostate.
    Morsi A; Jamal S; Silverberg JD
    Clin Endocrinol (Oxf); 1996 Jan; 44(1):121-4. PubMed ID: 8706284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gn-RH antagonist possible response, after Gn-RH agonist failure in a man with metastatic prostate cancer.
    Rocco B; Ferrari M; Scardino E; Matei DV; Verweij F; Varela R; De Cobelli O
    Anticancer Res; 2005; 25(1B):577-8. PubMed ID: 15816630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.